Page last updated: 2024-11-03

proadifen and Lung Diseases

proadifen has been researched along with Lung Diseases in 2 studies

Proadifen: An inhibitor of drug metabolism and CYTOCHROME P-450 ENZYME SYSTEM activity.

Lung Diseases: Pathological processes involving any part of the LUNG.

Research Excerpts

ExcerptRelevanceReference
" It is well established that the pneumotoxicity of MCT depends on its hepatic bioactivation to monocrotaline pyrrole (MCTP) and perhaps other toxic metabolites."1.27Effect of a mixed function oxidase inducer and inhibitor on monocrotaline pyrrole pneumotoxicity. ( Bruner, LH; Carpenter, LJ; Hamlow, P; Roth, RA, 1986)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kehrer, JP1
Witschi, H1
Bruner, LH1
Carpenter, LJ1
Hamlow, P1
Roth, RA1

Other Studies

2 other studies available for proadifen and Lung Diseases

ArticleYear
Effects of drug metabolism inhibitors on butylated hydroxytoluene-induced pulmonary toxicity in mice.
    Toxicology and applied pharmacology, 1980, Volume: 53, Issue:2

    Topics: Animals; Antimetabolites; Butylated Hydroxytoluene; DNA; Lung Diseases; Male; Mice; Mice, Inbred BAL

1980
Effect of a mixed function oxidase inducer and inhibitor on monocrotaline pyrrole pneumotoxicity.
    Toxicology and applied pharmacology, 1986, Sep-30, Volume: 85, Issue:3

    Topics: Animals; Enzyme Induction; Heart; Lung Diseases; Magnetic Resonance Spectroscopy; Mass Spectrometry;

1986